PRAGUE, April 26, 2010 /PRNewswire-FirstCall/ -- Ness
Technologies, Inc. (NASDAQ: NSTC and TASE: NSTC), a global provider
of information technology solutions and services, announced today
the start of an Oracle(R) E-Business Suite implementation at Teva
Czech Industries s.r.o., a provider of pharmaceutical products. The
new system will handle financial and logistics issues, replacing a
current QAD MFG/Pro system. The project, which is valued at
$2 million, is targeted to go into
production on January 1, 2011. Ness
will support the project through the end of April 2011. Teva Czech Industries is part of Teva
Pharmaceutical Industries, a global pharmaceutical company
specializing in the development, production and marketing of
generic and proprietary branded pharmaceuticals as well as active
pharmaceutical ingredients.
Teva Pharmaceutical Industries selected Ness, a leading provider
of IT services and solutions in Central and Eastern Europe, an Oracle Platinum Partner and
one of the region's leaders in the manufacturing segment, based on
its reputation as a reliable and proven partner who could
completely fulfill Teva's expectations regarding the new enterprise
system. Key factors for Teva were Ness' experience in similar
international projects, its professional approach and its large
team of dedicated Oracle E-Business Suite experts in Central and
Eastern Europe.
"Our company is strongly export focused, exporting over 80% of
our production, including to the highly complex markets in the U.S.
and Western Europe," said
Jiri Urbanec, CEO of Teva Czech
Industries. "Thanks to the launch of a new plant for solid
pharmaceutical drugs this year, we expect that our exports will
increase more than three times. In order to produce four billion
tablets annually for one of the toughest markets in the world, we
need to manage our financial and logistics processes with
world-class tools. The new system will not only simplify and
optimize Teva's production plant in Opava, Czech Republic, and its commercial units in
Prague, Czech Republic, and
Bratislava, Slovakia, but it will
also connect the two European countries to the Israeli offices of
its parent company, Teva Pharmaceutical Industries."
"Winning this important project confirms our dominant position
as a provider of Oracle E-Business Suite implementation services in
the Czech Republic. This is one of
the most important projects of this type," said Mirko Kalous, MBA, CEO of Ness Czech. "We have
been engaged with the Oracle E-Business Suite since its entry into
the Czech market 1993, when we participated in the localization and
the first implementations of the solution."
Ness has deployed and operated similar solutions for other
leading companies in their sectors, such as Vitkovice and Dalkia
Czech Republic. Manufacturing is an important sector for Ness,
where the company has a wide domain expertise. This expertise will
be used by Ness in the Teva project. The cooperation between Teva
and Ness is not limited only to the Czech market; as a regional
partner Ness is able to support Teva's strategy throughout the
whole region.
The Oracle E-Business Suite is a comprehensive suite of
integrated, global business applications, which provides a
complete, integrated business intelligence portfolio, the most
adaptable global business platform, and the most customer-focused
applications strategy. The Oracle E-Business Suite enables, for
example, asset life cycle management, customer relationship
management, enterprise resource planning, supply chain management
and more.
About Ness Technologies
Ness Technologies (NASDAQ: NSTC and TASE: NSTC) is a global
provider of IT and business services and solutions with specialized
expertise in software product engineering; system integration,
application development and consulting; and software distribution.
Ness delivers its portfolio of solutions and services using a
global delivery model combining offshore, near-shore and local
teams. With about 7,800 employees, Ness maintains operations in 18
countries, and partners with numerous software and hardware vendors
worldwide. For more information about Ness Technologies, visit
http://www.ness.com.
About Teva Czech Industries
Teva Czech Industries, based in Opava, Czech Republic, is a leading pharmaceutical
manufacturer with a long history. Its broad portfolio includes
generic medicines, over the counter drugs, active pharmaceutical
ingredients and plant extracts. The company's products meet
recognized quality standards and are exported to many countries
around the world, including the United
States and Western Europe.
Teva Czech Industries employs more than 1,000 employees, helping
the company reach its achievements and ambitious goals. In 2006 the
company became part of Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries Ltd., headquartered in
Israel, is among the top 20
pharmaceutical companies in the world and is a leading generic
pharmaceutical company. The company develops, manufactures and
markets generic and innovative pharmaceuticals and active
pharmaceutical ingredients. Over 80 percent of Teva's sales are in
North America and Western Europe. For more information about
Teva, visit http://www.tevapharm.com.
Forward Looking Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements often are preceded by words such
as "believes," "expects," "may," "anticipates," "plans," "intends,"
"assumes," "will" or similar expressions. Forward-looking
statements reflect management's current expectations, as of the
date of this press release, and involve certain risks and
uncertainties. Ness' actual results could differ materially from
those anticipated in these forward looking statements as a result
of various factors. Some of the factors that could cause future
results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors"
described in Ness' Annual Report of Form 10-K filed with the
Securities and Exchange Commission on March
15, 2010. Ness is under no obligation, and expressly
disclaims any obligation, to update or alter its forward-looking
statements, whether as a result of such changes, new information,
subsequent events or otherwise.
Trademarks
Oracle and Java are registered trademarks of Oracle Corporation and/or
its affiliates.
Media Contact:
David Kanaan
Intl: +972-54-425-5307
Email: media.int@ness.com
Investor Relations Contact:
Drew Wright
USA: +1-201-488-3262
Email: investor@ness.com
SOURCE Ness Technologies Inc